Lesniak, Wojciech G.
Chu, Chengyan
Jablonska, Anna
Behnam Azad, Babak
Zwaenepoel, Olivier
Zawadzki, Michal
Lisok, Ala
Pomper, Martin G.
Walczak, Piotr
Gettemans, Jan
Janowski, Miroslaw
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01NS091100, R01NS091110, R21NS106436)
National Institute of Biomedical Imaging and Bioengineering (P41 EB024495)
Article History
Received: 2 December 2018
Accepted: 29 April 2019
First Online: 3 June 2019
Compliance with ethical standards
:
: JAG has a financial and/or business interests in Gulliver Biomed BVBA, a company that licensed the tested nanobody; however, since the nanobody does not have a brain target there are no direct benefits to Gulliver Biomed. The remaining authors declared no conflict of interest related to the current work.
: All animal procedures were carried out under protocols approved by the Johns Hopkins Animal Care and Use Committee. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.